Find My Journal

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland, Erland Erdmann, Massimo Massi‐Benedetti, Ian K. Moules, Allan M. Skene, Meng H. Tan, Pierre J. Lefèbvre, Gordon Murray, Eberhard Standl, Robert G. Wilcox, Lars Wilhelmsen, John Betteridge, Kåre I. Birkeland, Alain Golay, Robert J. Heine, László Korányi, Markku Laakso, Marián Mokáň, Antanas Norkus, Valdis Pīrāgs, Toomas Podar, André Scheen, Werner A. Scherbaum, Guntram Schernthaner, Ole Schmitz, J Skrha, Ulf Smith, J Tatoń

The Lancet, 2005

St George's Hospital, University of Cologne, University of Perugia, Takeda (United Kingdom), Nottingham Biomedical Research Centre, Eli Lilly (United States), International Diabetes Federation, University of Edinburgh, German Center for Diabetes Research, University of Nottingham, University of Gothenburg, University College London, North Middlesex Hospital, University of Oslo, Oslo University Hospital, University Hospital of Geneva, Amsterdam UMC Location Vrije Universiteit Amsterdam, Kuopio University Hospital, Comenius University Bratislava, Competence Centre on Health Technologies (Estonia), University of Liège, Deutsches Diabetes-Zentrum e.V., Heinrich Heine University Düsseldorf, Rudolfinerhaus Hospital, Aarhus University, Medical University of Warsaw

View Free PDF Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

4115

Citations

View on Google Scholar